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Mitochondrial dysfunction underlies the pathogenesis of a variety of human neurodegenerative disorders, 
either directly, e.g., in the case of mitochondrial diseases, or indirectly, e.g. in the case of Parkinson’s disease. 
The complexity of these disorders has so far prevented the development of effective therapeutic strategies. 
We demonstrate that the microRNAs miR-181a and miR-181b (miR-181a/b) regulate key genes involved in 
mitochondrial biogenesis and function. We also show that these miRNAs are involved in the global regulation 
of mitochondrial turnover in the central nervous system through the simultaneous and fine tuning modulation 
of different gene pathways. We sought to verify whether the modulation of these miRNAs could be 
therapeutically exploited in neurodegenerative conditions associated to impaired mitochondrial activity. We 
show that miR-181a/b downregulation strongly protects neurons from cell death and significantly ameliorates 
the disease phenotype in in vivo models of both primary and secondary mitochondria-mediated 
neurodegeneration, such as Microphthalmia with Linear Skin Lesions, Leber hereditary optic neuropathy and 
Parkinson’s disease. Altogether our results indicate that miR-181a/b act as hubs in mitochondrial homeostasis 
in the central nervous system and represent novel gene-independent therapeutic targets for a wide-range of 
neurodegenerative diseases caused by mitochondrial dysfunction. 
 
